Insmed Inc INSM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Insmed Reports Second-Quarter 2024 Financial Results and Provides Business Update
-
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Insmed to Host Second-Quarter 2024 Financial Results Conference Call on Thursday, August 8, 2024
-
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Insmed's stock should triple after positive drug trial data, analyst says
Trading Information
- Previous Close Price
- $72.88
- Day Range
- $71.17–73.60
- 52-Week Range
- $21.92–80.53
- Bid/Ask
- $72.99 / $78.00
- Market Cap
- $12.55 Bil
- Volume/Avg
- 2.1 Mil / 2.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 32.83
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 912
- Website
- https://www.insmed.com
Comparables
Valuation
|
Metric
|
INSM
|
AVIR
|
TRVI
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 313.51 | 0.60 | 3.50 |
Price/Sales | 32.83 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
INSM
AVIR
TRVI
Financial Strength
|
Metric
|
INSM
|
AVIR
|
TRVI
|
|---|---|---|---|
Quick Ratio | 2.46 | 18.87 | 10.29 |
Current Ratio | 2.71 | 19.02 | 10.68 |
Interest Coverage | −9.15 | — | −4,780.89 |
Quick Ratio
INSM
AVIR
TRVI
Profitability
|
Metric
|
INSM
|
AVIR
|
TRVI
|
|---|---|---|---|
Return on Assets (Normalized) | −45.76% | −23.62% | −40.88% |
Return on Equity (Normalized) | — | −25.11% | −44.19% |
Return on Invested Capital (Normalized) | −60.89% | −29.21% | −48.62% |
Return on Assets
INSM
AVIR
TRVI
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Qtvchtvsv | Gtg | $518.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Xkqydvtxk | Wfzfhnq | $119.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Fycmpnml | Kkkkjz | $114.7 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Nfptvzt | Pvmjnb | $34.9 Bil | |||
| argenx SE ADR
ARGX
| Dwbzphnyh | Lvhc | $32.9 Bil | |||
| BioNTech SE ADR
BNTX
| Myyjctbb | Pnvf | $28.3 Bil | |||
| Moderna Inc
MRNA
| Lxmnmpnfs | Lbfvr | $24.3 Bil | |||
| United Therapeutics Corp
UTHR
| Fddxtmfb | Bwwtf | $15.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Xhljlqfb | Dssfv | $13.3 Bil | |||
| Incyte Corp
INCY
| Hjsztzs | Qdpzj | $13.0 Bil |
United States